Type 2 diabetes mellitus and osteoarthritis

Nicola Veronese, Cyrus Cooper, Jean Yves Reginster, Marc Hochberg, Jaime Branco, Olivier Bruyère, Roland Chapurlat, Nasser Al-Daghri, Elaine Dennison, Gabriel Herrero-Beaumont, Jean François Kaux, Emmanuel Maheu, René Rizzoli, Roland Roth, Lucio C. Rovati, Daniel Uebelhart, Mila Vlaskovska, André Scheen

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objectives: Type 2 diabetes mellitus (T2DM) and osteoarthritis (OA) are common diseases that frequently co-exist, along with overweight/obesity. While the mechanical impact of excess body weight on joints may explain lower limb OA, we sought to explore whether T2DM is linked to OA outside of excess weight and whether T2DM may play a role in OA pathophysiology. The consequence of T2DM on OA outcomes is a question of research interest. Methods: We conducted a critical review of the literature to explore the association between T2DM and OA, whether any association is site-specific for OA, and whether the presence of T2DM impacts on OA outcomes. We also reviewed the literature to assess the safety of anti-OA treatments in patients with T2DM. Results: T2DM has a pathogenic effect on OA through 2 major pathways involving oxidative stress and low-grade chronic inflammation resulting from chronic hyperglycemia and insulin resistance. T2DM is a risk factor for OA progression and has a negative impact on arthroplasty outcomes. Evidence is mounting for safety concerns with some of the most frequently prescribed anti-OA medications, including paracetamol, non-steroidal anti-inflammatory drugs, and corticosteroid injections, while other anti-OA medications may be safely prescribed in OA patients with T2DM, such as glucosamine and intra-articular hyaluronic acid. Conclusions: Future research is needed to better understand whether diabetes control and prevention can modulate OA occurrence and progression. The selection of therapy to treat OA symptoms in patients with T2DM may require careful consideration of the evidence based to avoid untoward safety issues.

Original languageEnglish
Pages (from-to)9-19
JournalSeminars in Arthritis and Rheumatism
Volume49
Issue number1
DOIs
Publication statusPublished - Aug 2019

Fingerprint

Osteoarthritis
Type 2 Diabetes Mellitus
Safety
Joints
Glucosamine
Hyaluronic Acid
Acetaminophen
Hyperglycemia
Arthroplasty
Insulin Resistance
Lower Extremity
Adrenal Cortex Hormones
Oxidative Stress
Anti-Inflammatory Agents
Obesity

Keywords

  • Obesity
  • Osteoarthritis
  • Pathophysiology
  • Safety
  • Type 2 diabetes mellitus

Cite this

Veronese, N., Cooper, C., Reginster, J. Y., Hochberg, M., Branco, J., Bruyère, O., ... Scheen, A. (2019). Type 2 diabetes mellitus and osteoarthritis. Seminars in Arthritis and Rheumatism, 49(1), 9-19. https://doi.org/10.1016/j.semarthrit.2019.01.005
Veronese, Nicola ; Cooper, Cyrus ; Reginster, Jean Yves ; Hochberg, Marc ; Branco, Jaime ; Bruyère, Olivier ; Chapurlat, Roland ; Al-Daghri, Nasser ; Dennison, Elaine ; Herrero-Beaumont, Gabriel ; Kaux, Jean François ; Maheu, Emmanuel ; Rizzoli, René ; Roth, Roland ; Rovati, Lucio C. ; Uebelhart, Daniel ; Vlaskovska, Mila ; Scheen, André. / Type 2 diabetes mellitus and osteoarthritis. In: Seminars in Arthritis and Rheumatism. 2019 ; Vol. 49, No. 1. pp. 9-19.
@article{c86a375ed73e4dd5b5c660ea0a4ba838,
title = "Type 2 diabetes mellitus and osteoarthritis",
abstract = "Objectives: Type 2 diabetes mellitus (T2DM) and osteoarthritis (OA) are common diseases that frequently co-exist, along with overweight/obesity. While the mechanical impact of excess body weight on joints may explain lower limb OA, we sought to explore whether T2DM is linked to OA outside of excess weight and whether T2DM may play a role in OA pathophysiology. The consequence of T2DM on OA outcomes is a question of research interest. Methods: We conducted a critical review of the literature to explore the association between T2DM and OA, whether any association is site-specific for OA, and whether the presence of T2DM impacts on OA outcomes. We also reviewed the literature to assess the safety of anti-OA treatments in patients with T2DM. Results: T2DM has a pathogenic effect on OA through 2 major pathways involving oxidative stress and low-grade chronic inflammation resulting from chronic hyperglycemia and insulin resistance. T2DM is a risk factor for OA progression and has a negative impact on arthroplasty outcomes. Evidence is mounting for safety concerns with some of the most frequently prescribed anti-OA medications, including paracetamol, non-steroidal anti-inflammatory drugs, and corticosteroid injections, while other anti-OA medications may be safely prescribed in OA patients with T2DM, such as glucosamine and intra-articular hyaluronic acid. Conclusions: Future research is needed to better understand whether diabetes control and prevention can modulate OA occurrence and progression. The selection of therapy to treat OA symptoms in patients with T2DM may require careful consideration of the evidence based to avoid untoward safety issues.",
keywords = "Obesity, Osteoarthritis, Pathophysiology, Safety, Type 2 diabetes mellitus",
author = "Nicola Veronese and Cyrus Cooper and Reginster, {Jean Yves} and Marc Hochberg and Jaime Branco and Olivier Bruy{\`e}re and Roland Chapurlat and Nasser Al-Daghri and Elaine Dennison and Gabriel Herrero-Beaumont and Kaux, {Jean Fran{\cc}ois} and Emmanuel Maheu and Ren{\'e} Rizzoli and Roland Roth and Rovati, {Lucio C.} and Daniel Uebelhart and Mila Vlaskovska and Andr{\'e} Scheen",
year = "2019",
month = "8",
doi = "10.1016/j.semarthrit.2019.01.005",
language = "English",
volume = "49",
pages = "9--19",
journal = "Seminars in Arthritis and Rheumatism",
issn = "0049-0172",
publisher = "W B SAUNDERS CO-ELSEVIER INC",
number = "1",

}

Veronese, N, Cooper, C, Reginster, JY, Hochberg, M, Branco, J, Bruyère, O, Chapurlat, R, Al-Daghri, N, Dennison, E, Herrero-Beaumont, G, Kaux, JF, Maheu, E, Rizzoli, R, Roth, R, Rovati, LC, Uebelhart, D, Vlaskovska, M & Scheen, A 2019, 'Type 2 diabetes mellitus and osteoarthritis', Seminars in Arthritis and Rheumatism, vol. 49, no. 1, pp. 9-19. https://doi.org/10.1016/j.semarthrit.2019.01.005

Type 2 diabetes mellitus and osteoarthritis. / Veronese, Nicola; Cooper, Cyrus; Reginster, Jean Yves; Hochberg, Marc; Branco, Jaime; Bruyère, Olivier; Chapurlat, Roland; Al-Daghri, Nasser; Dennison, Elaine; Herrero-Beaumont, Gabriel; Kaux, Jean François; Maheu, Emmanuel; Rizzoli, René; Roth, Roland; Rovati, Lucio C.; Uebelhart, Daniel; Vlaskovska, Mila; Scheen, André.

In: Seminars in Arthritis and Rheumatism, Vol. 49, No. 1, 08.2019, p. 9-19.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Type 2 diabetes mellitus and osteoarthritis

AU - Veronese, Nicola

AU - Cooper, Cyrus

AU - Reginster, Jean Yves

AU - Hochberg, Marc

AU - Branco, Jaime

AU - Bruyère, Olivier

AU - Chapurlat, Roland

AU - Al-Daghri, Nasser

AU - Dennison, Elaine

AU - Herrero-Beaumont, Gabriel

AU - Kaux, Jean François

AU - Maheu, Emmanuel

AU - Rizzoli, René

AU - Roth, Roland

AU - Rovati, Lucio C.

AU - Uebelhart, Daniel

AU - Vlaskovska, Mila

AU - Scheen, André

PY - 2019/8

Y1 - 2019/8

N2 - Objectives: Type 2 diabetes mellitus (T2DM) and osteoarthritis (OA) are common diseases that frequently co-exist, along with overweight/obesity. While the mechanical impact of excess body weight on joints may explain lower limb OA, we sought to explore whether T2DM is linked to OA outside of excess weight and whether T2DM may play a role in OA pathophysiology. The consequence of T2DM on OA outcomes is a question of research interest. Methods: We conducted a critical review of the literature to explore the association between T2DM and OA, whether any association is site-specific for OA, and whether the presence of T2DM impacts on OA outcomes. We also reviewed the literature to assess the safety of anti-OA treatments in patients with T2DM. Results: T2DM has a pathogenic effect on OA through 2 major pathways involving oxidative stress and low-grade chronic inflammation resulting from chronic hyperglycemia and insulin resistance. T2DM is a risk factor for OA progression and has a negative impact on arthroplasty outcomes. Evidence is mounting for safety concerns with some of the most frequently prescribed anti-OA medications, including paracetamol, non-steroidal anti-inflammatory drugs, and corticosteroid injections, while other anti-OA medications may be safely prescribed in OA patients with T2DM, such as glucosamine and intra-articular hyaluronic acid. Conclusions: Future research is needed to better understand whether diabetes control and prevention can modulate OA occurrence and progression. The selection of therapy to treat OA symptoms in patients with T2DM may require careful consideration of the evidence based to avoid untoward safety issues.

AB - Objectives: Type 2 diabetes mellitus (T2DM) and osteoarthritis (OA) are common diseases that frequently co-exist, along with overweight/obesity. While the mechanical impact of excess body weight on joints may explain lower limb OA, we sought to explore whether T2DM is linked to OA outside of excess weight and whether T2DM may play a role in OA pathophysiology. The consequence of T2DM on OA outcomes is a question of research interest. Methods: We conducted a critical review of the literature to explore the association between T2DM and OA, whether any association is site-specific for OA, and whether the presence of T2DM impacts on OA outcomes. We also reviewed the literature to assess the safety of anti-OA treatments in patients with T2DM. Results: T2DM has a pathogenic effect on OA through 2 major pathways involving oxidative stress and low-grade chronic inflammation resulting from chronic hyperglycemia and insulin resistance. T2DM is a risk factor for OA progression and has a negative impact on arthroplasty outcomes. Evidence is mounting for safety concerns with some of the most frequently prescribed anti-OA medications, including paracetamol, non-steroidal anti-inflammatory drugs, and corticosteroid injections, while other anti-OA medications may be safely prescribed in OA patients with T2DM, such as glucosamine and intra-articular hyaluronic acid. Conclusions: Future research is needed to better understand whether diabetes control and prevention can modulate OA occurrence and progression. The selection of therapy to treat OA symptoms in patients with T2DM may require careful consideration of the evidence based to avoid untoward safety issues.

KW - Obesity

KW - Osteoarthritis

KW - Pathophysiology

KW - Safety

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=85060749938&partnerID=8YFLogxK

U2 - 10.1016/j.semarthrit.2019.01.005

DO - 10.1016/j.semarthrit.2019.01.005

M3 - Article

VL - 49

SP - 9

EP - 19

JO - Seminars in Arthritis and Rheumatism

JF - Seminars in Arthritis and Rheumatism

SN - 0049-0172

IS - 1

ER -